<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690038</url>
  </required_header>
  <id_info>
    <org_study_id>20150925 / 20160077-01H</org_study_id>
    <nct_id>NCT02690038</nct_id>
  </id_info>
  <brief_title>Ig PRx in AECOPD: Pilot Study</brief_title>
  <official_title>Feasibility and Safety of Immunoglobulin (Ig) Prophylactic Treatment in COPD Patients With Frequent Exacerbations: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Biologicals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at immunoglobulin (Ig) treatment in hospitalized chronic obstructive
      lung disease (COPD) patients with frequent exacerbations.

      This is a Phase II, pilot randomized double blind control study, meaning this study will help
      assess if this research can be expanded to evaluate Ig treatment in patients with COPD. Ig
      treatment is a sterile solution of human immunoglobulin proteins given intravenously (in the
      vein). Immunoglobulins are part of the immune system and help the body fight infections.
      Participants will be assigned to either receiving the Ig treatment or normal saline as a
      control product every 4 weeks for 12 months.

      Participants will continue on current standard therapy as determined by their treating
      physician.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Average number of patients being recruited per month. The study meets primary outcome if at least 4 patients can be recruited per month on average.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence and protocol compliance</measure>
    <time_frame>104 weeks</time_frame>
    <description>Number and percentage of recruited patients adhere to the allocated treatment and protocol. We aim to achieve 80% adherence rate which is defined as at least 80% of patients adhere to 80% of allocated treatment and protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE</measure>
    <time_frame>104 weeks</time_frame>
    <description>This will be assessed by documentation of adverse events in patients treated with Ig treatment versus control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>104 weeks</time_frame>
    <description>The proportion of patients able to complete the treatment in the experimental arm during the study period versus in the control arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) rates</measure>
    <time_frame>104 weeks</time_frame>
    <description>AECOPD will be ascertained by monthly follow-up phone calls as well as questionnaires during study visits to detect inpatient/outpatient treatment for exacerbations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: Health status</measure>
    <time_frame>104 weeks</time_frame>
    <description>measured by the validated St. George Respiratory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: Quality of life</measure>
    <time_frame>104 weeks</time_frame>
    <description>validated quality of life measurement tool - EuroWol EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: % predicted FEV1</measure>
    <time_frame>104 weeks</time_frame>
    <description>FEV1 value will be measured using a hand held spirometer. FEV1 value will be recorded in Litres (L) and reported as a percent of their predicted value (using the NHANES III reference standards for predicted values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: FEV1/FVC</measure>
    <time_frame>104 weeks</time_frame>
    <description>FVC will be measured using a hand held spirometer, and will be recorded in Litres (L). Ratio of FEV1 and FVC will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: Health services use</measure>
    <time_frame>104 weeks</time_frame>
    <description>Number of non-study physician visits, emergency department (ED) and hospital admissions over the twelve-month study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy trend: Health care system cost</measure>
    <time_frame>104 weeks</time_frame>
    <description>we will take the perspective of healthcare system and will measure the cost of health services use and an intervention. Intervention cost includes medication, staff, and equipment cost.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Intervention Arm 1: Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline Ig &lt; 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
Baseline Ig &gt; or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Arm 2: Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline Ig &lt; 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
Baseline Ig &gt; or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin (IVIG)</intervention_name>
    <description>Baseline Ig &lt; 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.
Baseline Ig &gt; or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization</description>
    <arm_group_label>Intervention Arm 1: Treatment</arm_group_label>
    <other_name>Gamunex</other_name>
    <other_name>CBS IGIV-nex</other_name>
    <other_name>Privigen</other_name>
    <other_name>Octagam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Baseline Ig &lt; 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.
Baseline Ig &gt; or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization</description>
    <arm_group_label>Intervention Arm 2: Control</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized adult patient with AECOPD (clinically dominant AECOPD in the case of
             multiple co-morbidities eg. absence of overt lobar pneumonia or acute congestive heart
             failure or alternate diagnosis such as acute coronary syndrome or pulmonary embolism)

          -  Diagnosis of severe COPD (post bronchodilator FEV1 &lt;50%, FEV1/FVC ratio &lt;0.7) made by
             standard spirometry within previous 12 months or within three days of admission if
             previous PFT data is not available

          -  Age &gt;40 years

          -  &gt;10 pack year smoking history

          -  At least one COPD exacerbation in the previous 12 months before enrollment, defined by
             having had documented inpatient or outpatient treatment by physician with antibiotics
             and/or prednisone for physician diagnosed COPD exacerbation

          -  Expected to live &gt; 12 months

        Exclusion Criteria:

          -  Known severe hypersensitivity to immunoglobulin or its components (anaphylaxis)

          -  Underlying malignancy (including chronic lymphocytic leukemia)

          -  History of hematopoietic stem cell transplant or solid organ transplant

          -  Current treatment with a biological therapy for other conditions

          -  Concomitant significant immunodeficiency or on immunosuppressive treatment other than
             for COPD

          -  Alpha-1 antitrypsin deficiency

          -  Significant proteinuria (dipstick proteinuria ≥ 3+ or known urinary protein loss ≥ 2
             g/day or nephrotic syndrome) and/or has acute renal failure and/or severe renal
             impairment (creatinine more than 2.5 times the upper limit of normal and/or on
             dialysis)

          -  IgA deficiency (IgA &lt;0.1 g/L)

          -  Immunoglobulin therapy in the last 12 months or on current Ig therapy or have a
             clinical indication for Ig replacement therapy
             (www.nacblood.ca/resources/guidelines/IVIG.html)

          -  Obesity (BMI ≥35 kg/m²)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juthaporn Cowan, MD, PhD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Scientist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juthaporn Cowan, MD, PhD, FRCPC</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>73954</phone_ext>
    <email>jcowan@toh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Abdallah</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>77204</phone_ext>
      <email>saabdallah@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Trinidad</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>79617</phone_ext>
      <email>atrinidad@toh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.who.int/respiratory/copd/burden/en/</url>
    <description>WHO | Burden of COPD</description>
  </link>
  <link>
    <url>http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html#Burden.</url>
    <description>Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet - American Lung Association.</description>
  </link>
  <link>
    <url>http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ontario-health-technology-assessment-series/chronic-obstructive-pulmonary-disease-copd-evidentiary-framework</url>
    <description>Chronic Obstructive Pulmonary Disease (COPD) Evidentiary Framework - Health Quality Ontario (HQO).</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26119690.</url>
    <description>Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-re...</description>
  </link>
  <reference>
    <citation>Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron SD, Cameron DW. A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease. PLoS One. 2015 Nov 11;10(11):e0142205. doi: 10.1371/journal.pone.0142205. eCollection 2015.</citation>
    <PMID>26558756</PMID>
  </reference>
  <reference>
    <citation>Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005 Sep 6;143(5):317-26.</citation>
    <PMID>16144890</PMID>
  </reference>
  <reference>
    <citation>Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883.</citation>
    <PMID>20843247</PMID>
  </reference>
  <reference>
    <citation>Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22.</citation>
    <PMID>9603117</PMID>
  </reference>
  <reference>
    <citation>Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010 Jun;7(3):214-28. doi: 10.3109/15412555.2010.481697. Review.</citation>
    <PMID>20486821</PMID>
  </reference>
  <reference>
    <citation>Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, Bakke P, Agusti A, Anzueto A. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015 Apr;147(4):999-1007. doi: 10.1378/chest.14-0655.</citation>
    <PMID>25356881</PMID>
  </reference>
  <reference>
    <citation>Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis. 2013;8:551-9. doi: 10.2147/COPD.S51507. Epub 2013 Nov 12.</citation>
    <PMID>24348031</PMID>
  </reference>
  <reference>
    <citation>Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):689-98. doi: 10.1056/NEJMoa1104623. Erratum in: N Engl J Med. 2012 Apr 5;366(14):1356.</citation>
    <PMID>21864166</PMID>
  </reference>
  <reference>
    <citation>Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS; PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014 Mar;2(3):187-94. doi: 10.1016/S2213-2600(13)70286-8. Epub 2014 Jan 30. Erratum in: Lancet Respir Med. 2014 Apr;2(4):e4.</citation>
    <PMID>24621680</PMID>
  </reference>
  <reference>
    <citation>Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.</citation>
    <PMID>19716960</PMID>
  </reference>
  <reference>
    <citation>Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011 Aug;8(4):356-62. doi: 10.1513/pats.201102-016RM. Review.</citation>
    <PMID>21816992</PMID>
  </reference>
  <reference>
    <citation>Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.</citation>
    <PMID>25208464</PMID>
  </reference>
  <reference>
    <citation>Kawano T, Matsuse H, Obase Y, Kondo Y, Machida I, Tomari S, Mitsuta K, Fukushima C, Shimoda T, Kohno S. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol. 2002 Jul;128(3):240-3.</citation>
    <PMID>12119507</PMID>
  </reference>
  <reference>
    <citation>Yip NH, Lederer DJ, Kawut SM, Wilt JS, D'Ovidio F, Wang Y, Dwyer E, Sonett JR, Arcasoy SM. Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med. 2006 Apr 15;173(8):917-21. Epub 2006 Jan 6.</citation>
    <PMID>16399990</PMID>
  </reference>
  <reference>
    <citation>Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001 Sep 6;345(10):747-55. Review.</citation>
    <PMID>11547745</PMID>
  </reference>
  <reference>
    <citation>Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, Zinkernagel RM. Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999 Dec 10;286(5447):2156-9.</citation>
    <PMID>10591647</PMID>
  </reference>
  <reference>
    <citation>Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. doi: 10.1056/NEJMra1009433. Review.</citation>
    <PMID>23171098</PMID>
  </reference>
  <reference>
    <citation>Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ. 2015 Mar 3;187(4):257-64. doi: 10.1503/cmaj.130375. Epub 2015 Feb 9. Review.</citation>
    <PMID>25667260</PMID>
  </reference>
  <reference>
    <citation>Sabroe I, Postma D, Heijink I, Dockrell DH. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax. 2013 Dec;68(12):1085-7. doi: 10.1136/thoraxjnl-2013-203773. Epub 2013 Aug 8.</citation>
    <PMID>23929790</PMID>
  </reference>
  <reference>
    <citation>Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol. 2006 Jul;97(1):113-6.</citation>
    <PMID>16892792</PMID>
  </reference>
  <reference>
    <citation>Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011 Jun;164 Suppl 2:2-5. doi: 10.1111/j.1365-2249.2011.04387.x. Review.</citation>
    <PMID>21466545</PMID>
  </reference>
  <reference>
    <citation>Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010 Oct;137(1):21-30. doi: 10.1016/j.clim.2010.06.012. Epub 2010 Aug 1.</citation>
    <PMID>20675197</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AECOPD</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

